// App-Quantinova.ai

O_15 : MK-3682, a HCV NS5B Inhibitor with a Broad Spectrum of HCV Genotypic Activity, Demonstrates Potent Antiviral Activity in Genotypes -1,-2, and - 3 HCV-Infected Patients

Researchers

Presenter

  • W. Gao

Principal Investigators

  • X.S. Glasgow

  • W.L. Marshall

  • J. Sullivan-Bolyai

  • E.E. Marcantonio

  • L. Arrington

  • T. Crumley

  • M.F. Temam

  • E. Gane

  • W. Haazen

  • S. Popa

  • E. Sicard

  • C. Stedman

Medical Centers

  • Algorithme Pharma, Clinical Research Unit, Montreal, Canada

  • SGS Life Science Services, Clinical Pharmacology Unit, Antwerpen, Belgium

  • Christchurch Clinical Studies Trust, Christchurch, New Zealand

  • New Zealand Liver Transplant Unit, Auckland City Hospital, Auckland, New Zealand

  • Republican Hospital, Clinical Research Unit, Chisinau, Moldova

Locations

  • Canada

  • Moldova

  • Belgium

  • New Zealand

Companies

  • Merck & Co., Inc.

Study Components

Therapeutic Area

  • Gastroenterology (GU)

Disease

  • Cirrhosis

Biomarkers

  • N/A

Drug/Treatment

  • Uprifosbuvir

  • LCB100200

Outcome

  • Unknown

Study Design

  • randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved